Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

Study identifier:D9673R00005

ClinicalTrials.gov identifier:NCT04857619

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

Medical condition

Metastatic Breast Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

763

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 14 May 2021
Primary Completion Date: 31 Oct 2022
Study Completion Date: 31 Oct 2022

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria